Loading
BioAge Labs, Inc. Stock: price and insider trades · United States
US·Mcap US$255.6M
No insider purchase over the last 90 days. The latest was filed 10 Mar 2025.
BioAge Labs, Inc.: what insiders have been doing
BioAge Labs, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for BioAge Labs, Inc. logged 26 filings by 5 insiders.
No insider bought on the market over the period, while 3 insiders filed 4 sales totalling €3.8M. The totals exclude 2 filings filed without an amount. At €3.6M, the sale published on 15 January 2026 by Fortney Kristen is the largest of the period.
With 26 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. Looking back to 2024, when coverage begins, insiders filed 3 purchases and 4 sales.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€4M
4 ops. · all time
Who traded when
BuySaleShane Barton2 sales
Kristen Fortney1 sale
Paul D. Rubin1 sale
Since the insiders bought
- +356.1%Entry US$4.40 · Close at T+365 US$20.07
- +356.1%Entry US$4.40 · Close at T+365 US$20.07
- -74.3%Entry US$21.89 · Close at T+365 US$5.63
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BioAge Labs, Inc. Buy (bullish), based on 9 analysts. Average price target: US$32.56.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.57
Analyst consensus
9 analystsBuy
US$8.00Target US$32.56(+484%)US$73.00
Income statement
RevenueUS$9M
EBITDA-US$79.7M-886% margin
Net income-US$80.6M-896.1% margin
Valuation
PER (forward)-2.2x
P/Book0.7x
Beta1.08
Balance sheet & cash
Market capUS$255.6M
Total debtUS$5.6M
Free Cash Flow-US$82.3M
Debt / Equity1%
Profitability & ownership
ROE-28.2%
ROA-18.5%
% insiders2.4%
% institutions90.6%
Last declaration on 1 July 2026
Declarations33 total
9,301 sharesCommon StockSEC:0001836297-26-000005:0
7,261 sharesCommon StockSEC:0001836297-26-000005:1
8,958 sharesCommon StockSEC:0001836297-26-000005:2
14,198 sharesCommon StockSEC:0001836297-26-000005:3
42,350 sharesCommon StockSEC:0001836297-26-000005:4
4,290 sharesCommon StockSEC:0001836297-26-000005:5
4,000 sharesCommon StockSEC:0001836297-26-000005:6
4,065 sharesCommon StockSEC:0001836297-26-000005:7
7,861 sharesCommon StockSEC:0001836297-26-000005:8
20,216 sharesCommon StockSEC:0001836297-26-000005:9
20,216 shares@ US$25.18680.16% mcap31.3% of flowCommonSEC144:0001959173-26-004979
42,350 shares@ US$25.20840.33% mcap65.7% of flowCommonSEC144:0001959173-26-004955
3,542 shares@ US$4.380.0032% mcap5.4% of flowCommon StockSEC:0001120478-26-000013:0
5,437 shares@ US$4.113.4% of flowCommon StockSEC:0001210905-26-000011:0
3,383 shares@ US$6.573.3% of flowCommon StockSEC:0001210905-26-000011:1
8,820 shares@ US$17.8123.6% of flowCommon StockSEC:0001210905-26-000011:2
3,542 shares@ US$4.385.3% of flowCommon StockSEC:0001120478-26-000011:0
5,433 shares@ US$4.113.3% of flowCommon StockSEC:0001210905-26-000009:0
3,541 shares@ US$4.385.2% of flowCommon StockSEC:0001120478-26-000007:0
5,433 shares@ US$4.113.3% of flowCommon StockSEC:0001210905-26-000005:0
3,542 shares@ US$4.385.4% of flowCommon StockSEC:0001120478-26-000005:0
233,107 shares@ US$18.1163100.0% of flowCommon StockSEC:0002032751-26-000003:0
27,000 shares@ US$8.3978.6% of flowCommon StockSEC:0001120478-26-000003:0
5,433 shares@ US$4.113.3% of flowCommon StockSEC:0001210905-26-000002:0
18,000 shares@ US$6.5717.7% of flowCommon StockSEC:0001210905-25-000006:0
25 of 33 declarations
About BioAge Labs, Inc.
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to extend lifespan by targeting the mechanisms of aging. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
